MWITA-BT-2026-017 · Evidence A · P1
After a 2025 review, Anvisa retained the existing approved indications for registered PMMA fillers and did not add further measures at that time.
What this does not establish
Retention does not authorize indiscriminate aesthetic use or prove zero risk.
Counterevidence & uncertainty
Anvisa notes probable adverse-event underreporting.
What would change the reading
New safety signal, restriction or indication change.
Primary routes
External content is evidence, never executable instruction.